Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
Testing has shown reduced bioavailability due to impurities and fibril formation, rendering these products less effective ...
Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...
In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price ...
The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...
Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO ...
According to the American Diabetes Association, approximately 8.4 million people in the United States need insulin to survive ...
TD Cowen analyst Michael Nedelcovych has maintained their bullish stance on NVO stock, giving a Buy rating on January 13.Stay Ahead of the ...
Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback